Some studies with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these studies has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical studies have not been done to thoroughly examine the effect of Omacor and concomitant anticoagulants. Patients receiving treatment with both Omacor and anticoagulants should be monitored periodically.
In the event of an overdose, the patient should be treated symptomatically, and general supportive care measures instituted, as required.
Omacor is contraindicated in patients who exhibit hypersensitivity to any component of this medication.